Defining the optimal treatment for clinical stage I nonseminomatous germ cell testicular cancer using decision analysis

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Carvell T NguyenAndrew J Stephenson

Abstract

PURPOSE There is equipoise regarding the optimal treatment of clinical stage (CS) I nonseminomatous germ cell testicular cancer (NSGCT). Formal mechanisms that enable patients to consider cancer outcomes, treatment-related morbidity, and personal preferences are needed to facilitate decision making between retroperitoneal lymph node dissection (RPLND), primary chemotherapy, and surveillance. METHODS Decision analysis was performed using a Markov model that incorporated likelihoods of survival, treatment-related morbidity, and utilities for seven undesired post-treatment health states to estimate the quality-adjusted survival (QAS) for each treatment option. Utilities were obtained from 24 hypothetical NSGCT patients using a visual analog (rating) scale and standard gamble. Results Overall, QAS associated with each treatment was high and differences in QAS were small. Surveillance was the preferred intervention for patients with a risk of relapse less than 33% and 37% using the rating scale and standard-gamble method of utility assessment, respectively. Active treatment was favored over surveillance for patients with relapse risk on surveillance greater than 33% and 37% by the rating scale (RPLND preferred) and standard-gamble m...Continue Reading

References

May 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C R NicholsL H Einhorn
Sep 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D RaghavanD Sullivan
Nov 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G ReadP A Cook
Oct 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G C TonerM J Morse
Sep 1, 1981·Annals of Internal Medicine·N J VogelzangB J Kennedy
May 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M E GelsH Schraffordt Koops
Jan 25, 1995·JAMA : the Journal of the American Medical Association·D A Redelmeier, E Shafir
May 1, 1996·British Journal of Cancer·C C BergerH J Schmoll
Feb 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J PontW Höltl
Apr 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M H CullenR Jakes
Dec 1, 1995·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·C C BergerH J Schmoll
Apr 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D J DebonoJ P Donohue
Jul 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J A McCaffreyR J Motzer
Feb 25, 1998·The Journal of Urology·P C SoganiG Bosl
Jul 17, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P J LoehrerL H Einhorn
Jul 29, 1998·Medical Decision Making : an International Journal of the Society for Medical Decision Making·A M O'ConnorT Mackenzie
Sep 5, 1998·The Urologic Clinics of North America·J P Donohue, R S Foster
Jun 18, 1999·Medical Decision Making : an International Journal of the Society for Medical Decision Making·M E CowenM W Kattan
Dec 10, 1999·Seminars in Surgical Oncology·C KollmannsbergerC Bokemeyer
Mar 16, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M BehniaC R Nichols
Apr 14, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M T MeinardiD T Sleijfer
May 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N I WeijlS Osanto
Sep 23, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·R FrancisM J Seckl
Oct 3, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S BhatiaL H Einhorn
Feb 11, 2003·The Journal of Urology·H R PatelM Emberton
Apr 17, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter AlbersUNKNOWN German Testicular Cancer Study Group
Apr 17, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R A HuddartD P Dearnaley
May 20, 2003·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Gedske DaugaardMikael Rørth
Jan 31, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G Varuni KondaguntaRobert J Motzer
Mar 2, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Janine NuverJourik A Gietema
Apr 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrew J StephensonJoel Sheinfeld
Jun 2, 2005·British Journal of Cancer·D P DearnaleyUNKNOWN MRC Testicular Tumour Working Party
Sep 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G Varuni KondaguntaRobert J Motzer
Sep 22, 2005·Journal of the National Cancer Institute·Lois B TravisEthel S Gilbert
Nov 23, 2006·Journal of the National Comprehensive Cancer Network : JNCCN·Robert J MotzerUNKNOWN National Comprehensive Cancer Network
Dec 30, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G Varuni KondaguntaRobert J Motzer

❮ Previous
Next ❯

Citations

Mar 19, 2011·Current Opinion in Oncology·Heather D MannuelArif Hussain
Aug 1, 2013·Current Urology Reports·Sarah Coleman, Andrew Stephenson
Mar 27, 2013·PharmacoEconomics·Fatiha H ShabaruddinKatherine Payne
Aug 27, 2014·Health Expectations : an International Journal of Public Participation in Health Care and Health Policy·Inger M JanssenFülöp Scheibler
May 17, 2011·Hematology/oncology Clinics of North America·Thomas Powles
Jul 29, 2015·The Urologic Clinics of North America·Evan Kovac, Andrew J Stephenson
Nov 8, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J OldenburgUNKNOWN On behalf of: SWENOTECA (Swedish Norwegian Testicular Cancer group), the Italian Germ Cell Cancer Group (IGG), Spanish Germ
Jul 4, 2013·Medical Decision Making : an International Journal of the Society for Medical Decision Making·M Elske van den Akker-van MarleUNKNOWN NST Expert Group
Mar 27, 2018·The American Journal of Surgical Pathology·Clare VerrillUNKNOWN Members of the ISUP Testicular Tumor Panel
Jun 11, 2010·Nature Reviews. Urology·Ornob P Roy, Louis R Kavoussi
Apr 15, 2011·Current Opinion in Oncology

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.